Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01124864
Other study ID # CAUY922A2206
Secondary ID 2010-020116-11
Status Completed
Phase Phase 2
First received May 14, 2010
Last updated February 2, 2016
Start date October 2010
Est. completion date August 2014

Study information

Verified date February 2016
Source Novartis
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationNetherlands: Medicines Evaluation Board (MEB)Singapore: Clinical Trials & Epidemiology Research Unit (CTERU)Canada: Health CanadaGermany: Federal Institute for Drugs and Medical DevicesNorway: Norwegian Medicines AgencySouth Korea: Korea Food and Drug Administration (KFDA)Spain: Ministry of HealthTurkey: Ministry of Health
Study type Interventional

Clinical Trial Summary

This study will assess the efficacy of AUY922, when administered weekly at 70 mg/m2, in adult patients with advanced Non-small-cell Lung Cancer (NSCLC), who have received at least two prior lines of chemotherapy. Patients will be retrospectively, and prospectively, stratified based on their molecular tumor etiology. The following strata was assigned: Patients with Epidermal growth factor receptor (EGFR) activating mutations, Patients with Kirstin Raus sarcoma virus (KRAS) activating mutations, Patients with EML4-ALK (anaplastic lymphoma kinase) translocations and patients that were both EGFR and Kras wild type.


Recruitment information / eligibility

Status Completed
Enrollment 153
Est. completion date August 2014
Est. primary completion date August 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with histologically or cytologically confirmed advanced (stage IIIB or stage IV) NSCLC who have received at least two prior lines of treatment. Patients who, in the investigators opinion, are deemed unsuitable for the standard 2nd line chemotherapy will be eligible for protocol participation. One of the prior lines must have included a platinum agent. Prior treatment with a platinum agent is not a requirement for EGFR mutant patients and patients with EML4-ALK translocations

- Patients enrolled to the fifth stratum, modified EGFR mutant, must have documented prior response to EGFR TKI as defined by CR, PR or SD for 6 months or greater unless patient has de novo resistance to EGFR TKI (e.g. exon 20 insertions.)

- All patients must have at least one measurable lesion as defined by RECIST criteria. Previously irradiated lesions are not measurable unless the lesion is new or has demonstrated clear progression after radiation

- World Health Organization (WHO) performance status = 2. For patients enrolled to the fifth stratum, modified EGFR mutant, World Health Organization (WHO) performance status = 1

- Patients enrolled to the fifth stratum, modified EGFR mutant, must be willing and suitable to undergo fresh baseline biopsy prior to study treatment (unless patient had recent biopsy after EGFR TKI progression that concluded resistance to EGFR TKI.)

- Hematologic:

- Absolute Neutrophil Count (ANC) = 1.5 x 109/L.

- Hemoglobin (Hgb) = 9 g/dl.

- Platelets (plt) = 100 x 109/L.

Biochemistry:

- Total calcium (corrected for serum albumin) within normal limits or correctable with supplements.

- Magnesium within lower normal limits or correctable with supplements.

Adequate liver function defined as:

- AST/SGOT and ALT/SGPT = 3.0 x Upper limit of Normal (ULN) or = 5.0 x ULN if liver metastasis are present.

- Serum bilirubin = 1.5 x ULN.

- Serum albumin > 2.5 g/dL.

- Serum creatinine = 1.5 x ULN or 24 hour clearance = 50 mL/min.

Exclusion Criteria:

- Patients who have received more than four lines of prior treatment. Exception: Patients enrolled to the fifth stratum, modified EGFR mutant, must not have received more than two prior lines of therapy. Chemotherapy administered as adjuvant treatment more than six months prior to study enrollment is not considered a prior line of therapy for purposes of this study.

- Patients with a history of CNS metastasis. Note: Patients without clinical signs and symptoms of CNS involvement are not required to have MRI of the brain. Exception: Patients with treated brain metastases who are asymptomatic, who has discontinued corticosteroids, and who have been clinically stable for one month will be eligible for protocol participation. This exception is not valid for patients enrolled to the fifth stratum, modified EGFR mutant. These patients must not have CNS involvement.

- Prior anti-neoplastic treatment with any HSP90 or HDAC inhibitor compound.

- Patients must not have received:

- any systemic anti-cancer treatment or radiotherapy within 4 weeks prior to first dose of study treatment and should have recovered to baseline or less than Grade 1 from toxicities of such therapy prior to the first dose of study treatment

- 2 weeks for palliative radiotherapy to bones, 6 weeks for nitrosoureas and mitomycin

- 4 weeks for monoclonal antibodies

- and =5 half-life of the agent or active metabolites [if any] for continuous systemic anti-cancer treatment or investigational

- Patients who do not have either an archival tumor sample available or are unwilling to have a fresh tumor sample collected at baseline.

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
AUY922
AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.

Locations

Country Name City State
Canada Novartis Investigative Site Edmonton Alberta
Canada Novartis Investigative Site Montreal Quebec
France Novartis Investigative Site Creteil
France Novartis Investigative Site Marseille cedex 20
France Novartis Investigative Site Villejuif Cedex
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Oldenburg
Korea, Republic of Novartis Investigative Site Seoul Korea
Korea, Republic of Novartis Investigative Site Seoul Korea
Korea, Republic of Novartis Investigative Site Seoul Korea
Korea, Republic of Novartis Investigative Site Seoul Korea
Netherlands Novartis Investigative Site Amsterdam
Netherlands Novartis Investigative Site Groningen
Norway Novartis Investigative Site Oslo
Singapore Novartis Investigative Site Singapore
Spain Novartis Investigative Site Badalona Catalunya
Spain Novartis Investigative Site Barcelona Catalunya
Turkey Novartis Investigative Site Izmir
United States St. Luke's Hospital and Health Network St Luke's Bethlehem Pennsylvania
United States Dana Farber Cancer Institute DFCI Boston Massachusetts
United States University of California at Los Angeles UCLA - Santa Monica Los Angeles California
United States Maryland Oncology Hematology, P.A. Dept. of Assoc. Onc/Hem Rockville Maryland

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Canada,  France,  Germany,  Korea, Republic of,  Netherlands,  Norway,  Singapore,  Spain,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response Assessment by Study Stratum - Per Investigator Assessment The primary endpoint of the study was the investigator assessment of efficacy at 18 weeks in terms of response complete response (CR)/partial response (PR), stable disease (SD), or non clinical benefit (NCB) as assessed by response evaluation criteriain solid tumors (RECIST) version 1.0. ORR = patients with confirmed complete or partial response. Stable disease at 18 weeks = patients without response and with no assessment of progressive disease up to 18 weeks, but with an assessment of stable disease or better either within 2 weeks prior to the 18 week time point, or at the next non-missing assessment after the 18 week time point. No clinical benefit = all other patients. 18 weeks No
Secondary Overall Survival Rate Using Kaplan Meier Estimates - Per Investigator Radiological Review Overall survival (OS) is defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival was censored at the date of last contact. Week 12, Week 18 No
Secondary Progression Free Survival (PFS) Rate as Per Investigator Using Kaplan Meier Estimates - Per Investigator Radiological Review Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient did not have an event, progression-free survival was censored at the date of last adequate tumor assessment. A Novartis modified response evaluation criteria in solid tumors RECIST 1.1 criteria was applied to CT/MRI imaging data when assessing any responses to AUY922 treatment. All images were evaluated locally by the investigator. All complete or partial responses were confirmed by a second assessment at least 4 weeks later. Week 12, Week 18 No
Secondary Pharmacokinetics (PK) of Plasma Concentration of AUY922 and Its Metabolite BJP762: AUCinf Summary of PK parameters for all patients one hour post 70 mg/m2 AUY922 infusion for area under the curve infinity. There are discrepancies between sample numbers and study population because PK samples were not collected from all study subjects and thus were not analyzed. 1 hour after infusion No
Secondary Pharmacokinetics (PK) of Plasma Concentration of AUY922 and Its Metabolite BJP762: AUClast Summary of PK parameters for all patients one hour post 70 mg/m2 AUY922 infusion for area under the curve last. There are discrepancies between sample numbers and study population because PK samples were not collected from all study subjects and thus were not analyzed. 1 hour after infusion No
Secondary Pharmacokinetics (PK) of Plasma Concentration of AUY922 and Its Metabolite BJP762: Cmax Summary of PK parameters for all patients one hour post 70 mg/m2 AUY922 infusion for concentration max. There are discrepancies between sample numbers and study population because PK samples were not collected from all study subjects and thus were not analyzed. 1 hour after infusion No
See also
  Status Clinical Trial Phase
Terminated NCT02495233 - A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) Phase 1/Phase 2
Withdrawn NCT02672358 - Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC Phase 2
Recruiting NCT05815472 - Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT) N/A
Not yet recruiting NCT05900219 - Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study Phase 2
Not yet recruiting NCT04560244 - A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment Phase 2
Not yet recruiting NCT02907606 - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study N/A
Completed NCT01924416 - Lung Cancer Information Study (LCIS-R01) N/A
Completed NCT01136083 - Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients N/A
Completed NCT00831454 - Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection N/A
Completed NCT00363766 - Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Completed NCT00913705 - Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer Phase 3
Completed NCT01383135 - Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 Early Phase 1
Completed NCT00049998 - Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer Phase 3
Terminated NCT05061537 - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT03320044 - Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
Recruiting NCT04895930 - Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC Phase 2
Recruiting NCT03267654 - Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance Phase 2
Recruiting NCT04401059 - Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study Phase 4
Not yet recruiting NCT02938546 - 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study Phase 3
Completed NCT02965391 - Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients